If memory serves Sava had a bit of house cleaning, well deserved.
Just observing, last I recall reading is their 'developments' may have other applications, such as for seizure control.
Chart to me indicates more basing, and yah, proof in the pudding now. They screwed the pooch and that is hard to recover from.
Tweets
Key Developments
- Program Shift: Following the failure of two late-stage trials for its Alzheimer's drug, the company has completely discontinued the program. The primary focus is now on developing simufilam for TSC-related epilepsy, with a proof-of-concept clinical study planned for the first half of 2026.
- Insider Stock Purchase: CEO Richard Barry made a significant insider purchase of shares in September 2025, the first in over a year, which led to a temporary 50% surge in the stock price and a shift in market sentiment despite ongoing challenges.
- Financials and Ratings: For Q2 2025, Cassava reported a net loss of $44.2 million, primarily due to a litigation settlement contingency. The stock has been highly volatile, trading near its 52-week low, and recently received a "sell (D-)" rating from Weiss Ratings.
- Leadership and Operations: The company has appointed new experienced professionals to its clinical and scientific teams and implemented cost-reduction measures, including a 33% workforce reduction.
|
